Harmony Biosciences Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Harmony Biosciences Holdings generated cash of $219,387,000, which is more than the previous year. Cash used in financing activities reached the amount of -$105,552,000 last year. Net change in cash is therefore $67,396,000.
Cash Flow
| 2018 | -38.79M | -1.34M | 21.61M |
|---|---|---|---|
| 2019 | -75.43M | -127.14M | 143.76M |
| 2020 | -2.98M | -2.00M | 209.16M |
| 2021 | 98.55M | -100.29M | 7.41M |
| 2022 | 144.46M | -141.83M | 6.84M |
| 2023 | 219.38M | -46.43M | -105.55M |
HRMY Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 244.53M | 235.05M | 229.38M | 25.20M | 84.02M | 102.54M |
Operating activities | ||||||
Net income | 128.85M | 181.46M | 34.59M | -36.94M | -151.97M | -39.89M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 24.35M | 23.38M | 18.84M | 10.23M | 3.21M | 184K |
Stock-based compensation expense | 31.70M | 26.17M | 15.65M | 4.69M | 9.90M | 0 |
| Deferred income tax benefit | 31.70M | 26.17M | 15.65M | 4.69M | 9.90M | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -19.4M | -19.89M | -12.66M | -17.92M | -4.25M | 0 |
Inventories | -1.06M | 135K | -609K | -2.73M | -1.08M | 0 |
Accounts payable | 8.94M | 2.78M | -1.55M | -3.80M | 4.89M | -610K |
Cash generated by operating activities | 219.38M | 144.46M | 98.55M | -2.98M | -75.43M | -38.79M |
Investing activities | ||||||
Purchases Of Investments | -127.46M | -110.72M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -312K | -40.17M | -100.29M | -2.00M | -127.14M | -1.34M |
Acquisitions Net | -36.96M | 141.83M | -100M | -2M | -52M | 0 |
Cash generated by investing activities | -46.43M | -141.83M | -100.29M | -2.00M | -127.14M | -1.34M |
Financing activities | ||||||
Common Stock Issued | 0 | 8.84M | 30M | 147.62M | 50.08M | 25M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -100M | 0 | 0 | -167K | -1.13M | -3.2M |
Repayments of term debt | -1.25M | -2M | -222.5M | -120.58M | 100M | 0 |
Cash used in financing activities | -105.55M | 6.84M | 7.41M | 209.16M | 143.76M | 21.61M |
Net Change In Cash | 67.39M | 9.47M | 5.67M | 204.17M | -58.81M | -18.52M |
Cash at end of period | 311.93M | 244.53M | 235.05M | 229.38M | 25.20M | 84.02M |
| Data source | Data source | Data source | Data source |